In lung and pancreatic cancers, SMYD3 appeared to remain in the cell cytoplasm, where it functioned with the substrate MAP3K2 to enhance signaling through KRas to Erk1/2 [120]. This evidence concerns the gene SMYD3 and familial pancreatic carcinoma.